Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia

ABSTRACT Background Real‐world evidence for hypomethylating agent (HMA) + venetoclax 50 mg (VEN50) with voriconazole and posaconazole in acute myeloid leukemia (AML), is limited. Methods We evaluated outcomes of patients with newly‐diagnosed AML treated with HMA + VEN50 with either posaconazole (n =...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Kendall Diebold, Devan Parker, Sarah Worth, Manuel Espinoza‐Gutarra, Pankit Vachhani, Kimo Bachiashvili, Sravanti Rangaraju, Razan Mohty, Ravi Bhatia, Omer Jamy
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Wiley 2025-06-01
Ráidu:	eJHaem
Fáttát:	acute myeloid leukemia (AML) posaconazole Venetoclax 50 mg voriconazole
Liŋkkat:	https://doi.org/10.1002/jha2.70049
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!